ScreenerHero

IVVDInvivyd Inc. Common Stock

NAS · US · Healthcare · Biotechnology · invivyd.com
0.9965USD+3.86%Mkt Cap: 293.73M $P/E: —

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. T…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap293.73M $
Enterprise Value128.57M $
Revenue (TTM)58.37M $
Gross Profit49.68M $
Net Income (TTM)-52.49M $
Revenue/Share0.2160 USD
Last Price0.9965 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees122
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.73
PEG—
EV/EBITDA-1.15
EV/Revenue2.20
P/S4.80
P/B1.32
EPS (TTM)-0.31
EPS (Forward)-0.55
52W Range
0.483020% of range3.070
52W High3.070 USD
52W Low0.4830 USD
Profitability
Gross Margin92.99%
Oper. Margin-320.76%
EBITDA Margin-191.70%
Profit Margin-98.25%
ROE-21.73%
ROA-18.96%
Growth
Revenue Growth21.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-58.13M $
CapEx (TTM)155.00K $
FCF Margin-119.85%
FCF Yield-23.81%
Net Debt-151.69M $
Net Debt/EBITDA1.36
Balance Sheet
Debt/Equity0.01
Current Ratio5.87
Quick Ratio5.54
Book Value/Sh0.7180 USD
Cash/Share0.5430 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+903.5%
Target Range10.00 USD – 10.00 USD
# Analysts3
Ownership
Shares Out.294.76M
Float208.18M
Insiders7.16%
Institutions86.41%
Short Interest
Short Ratio8.3d
Short % Float10.43%
Short % Out.9.44%
Shares Short27.80M
Short (prev mo.)27.44M
Technical
SMA 500.7722 (+29.0%)
SMA 2001.542 (-35.4%)
Beta0.71
S&P 52W Chg18.16%
Avg Vol (30d)2.99M
Avg Vol (10d)3.92M
Technical Indicators
RSI (14)69.3
MACD0.0245
MACD Signal-0.0251
MACD Hist.+0.0495
BB Upper0.9191 USD
BB Middle0.6704 USD
BB Lower0.4216 USD
BB Width74.21%
ATR (14)0.0864 USD
Vol Ratio (20d)1.69x